-

Cytovance Biologics Expands Services With In-House Formulation Development

OKLAHOMA CITY--(BUSINESS WIRE)--Cytovance Biologics, a U.S.-based Contract Development and Manufacturing Organization (CDMO), announced the launch of its in-house formulation development services, significantly expanding its service offerings to biotech and pharmaceutical clients. This strategic enhancement reinforces the company’s position as a full-service partner for biologic drug developers.

Bringing formulation expertise in-house not only strengthens our technical capabilities but also reinforces Team Cytovance's mission to deliver smarter, faster, and more reliable development paths for our clients.

Share

“Adding formulation development capabilities is a major milestone for us,” said Axel Schleyer, Chief Commercial Officer of Cytovance Biologics. “It allows us to better serve our clients by accelerating development timelines and providing a truly integrated one-stop-shop approach, all while maintaining the highest standards of quality and regulatory compliance.”

This expansion reflects Cytovance’s continued investment in innovation and commitment to delivering comprehensive solutions for complex development challenges.

“Our formulation development workflow is grounded in Quality by Design (QbD) principles to deliver speed, safety, and data-driven precision from the outset,” added Fuad Haddadin, Head of R&D at Cytovance Biologics. “Bringing formulation expertise in-house not only strengthens our technical capabilities but also reinforces our mission to deliver smarter, faster, and more reliable development paths for our clients.”

The new services are now available to support existing and future client programs. Cytovance will showcase this and other offerings in Booth #606 at the BioProcess International conference in Boston this month.

About Cytovance:

Cytovance Biologics is an established large molecule CDMO that is large enough to support you at every stage and small enough to stay agile, providing your program with the care it deserves. For 20 years, Team Cytovance has offered flexibility and ingenuity across a full range of integrated services, supporting mammalian- and microbial-derived products on their journey from molecule to commercial manufacturing.

Follow us on LinkedIn: @Cytovance Biologics

Contacts

Media Inquiries: media@elementcg.co

Industry:

Cytovance Biologics

Release Summary
Cytovance Biologics launches in-house formulation development, expanding end-to-end CDMO services for biotech and pharma customers.
Release Versions
English

Contacts

Media Inquiries: media@elementcg.co

Social Media Profiles
Keep up with Team Cytovance
More News From Cytovance Biologics

Cytovance Biologics Launches Standalone Analytical Services to Accelerate Biologics Development

OKLAHOMA CITY--(BUSINESS WIRE)--Cytovance Biologics, a leading US-based contract development and manufacturing organization (CDMO) serving the biopharmaceutical industry, today announced the expansion of its analytical services portfolio with standalone analytical capabilities for biotechnology and pharmaceutical clients. The new approach provides access to Cytovance's experienced analytical team and regulatory-ready analytical solutions without requiring a manufacturing engagement. Building on...

Cytovance Biologics Expands Process Development Services with Perfusion Capabilities

OKLAHOMA CITY--(BUSINESS WIRE)--Cytovance Biologics, a leading US-based contract development and manufacturing organization (CDMO) serving the biopharmaceutical industry, today announced the expansion of its upstream process development offerings with the addition of perfusion capabilities. The new capability provides biopharmaceutical companies with an additional process development option alongside traditional fed-batch manufacturing, enabling Cytovance to better support programs requiring hi...

Cytovance Biologics Launches In-House Cell Line Development with High-Yield Titers up to 10g/L

OKLAHOMA CITY--(BUSINESS WIRE)--Cytovance Biologics®, a leading US-based contract development and manufacturing organization (CDMO) serving the biopharmaceutical industry, today announced the expansion of its mammalian cell culture capabilities with the addition of cell line development services, strengthening its ability to provide a seamless path from DNA to IND submission for its customers. The launch of new cell line development services reflects Cytovance’s continued investment in innovati...
Back to Newsroom